Stocks
Aprea Therapeutics, Inc.APRE
NASDAQHealthcareBiotechnology$0.52
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies for cancer, with a focus on synthetic lethality and DNA damage response pathways. Its lead candidate, APR-246, targets mutant p53 and is in late-stage trials for myelodysplastic syndromes. Investors track APRE for its potential in precision oncology and its pipeline of small-molecule drugs.
52W Range: $0.49-$1.49
Congressional Interest in Aprea Therapeutics, Inc. (APRE)
No congressional trades have been disclosed for Aprea Therapeutics, Inc. (APRE) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading APRE?
No congressional trades found for this stock.